Morepen Laboratories Limited has informed the Exchange about Investor Presentation
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Morepen Laboratories reported Q1'FY26 standalone revenue of Rs. 395 Cr (vs Rs. 385 Cr in Q4'FY25), but EBITDA fell sharply to Rs. 23 Cr from Rs. 33 Cr, with PAT dropping to Rs. 8 Cr from Rs. 12 Cr. The Medical Devices segment was the bright spot, recording highest-ever quarterly glucometer sales of 10.63 lakh units (72% YoY jump) and quarterly revenue growth of 16% YoY to Rs. 161 Cr. The Pharma/API business remained weak, with quarterly revenue declining to Rs. 205 Cr from Rs. 224 Cr YoY, hurt by export headwinds (Europe share fell from 32.6% to 22.6%). Management acknowledged margin pressure from low price realisation, higher input costs, and rising fixed costs, and expects business to stabilise over the next 2-3 quarters as geopolitical issues ease.
Near-term margin pressure is a concern, but record medical devices momentum and a strong 15.3 million customer base provide growth support. Investors should watch for stabilisation of API margins and execution of the plan to add 1,000 medical representatives in 3 years.